Skip to main content

Drug Interactions between deferasirox and zaleplon

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

zaleplon deferasirox

Applies to: zaleplon and deferasirox

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of zaleplon. According to the prescribing information, CYP450 3A4 is a minor metabolizing enzyme of zaleplon. When zaleplon was coadministered with the potent CYP450 3A4 inducer rifampin (600 mg daily for 14 days), zaleplon plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 80%. The extent to which other, less potent CYP450 3A4 inducers may interact with zaleplon is unknown.

MANAGEMENT: Caution is advised when zaleplon is coadministered with CYP450 3A4 inducers. Monitoring for diminished therapeutic response to zaleplon is recommended.

References

  1. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories

Switch to consumer interaction data

Drug and food interactions

Moderate

zaleplon food

Applies to: zaleplon

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of zaleplon. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

ADJUST DOSING INTERVAL: Administration of zaleplon with a high-fat or heavy meal may delay the onset of hypnotic effects. In healthy adult subjects, administration of zaleplon with a high-fat meal resulted in a 2-hour delay in the time to reach peak plasma drug concentration (Tmax) and a 35% reduction in the peak plasma drug concentration (Cmax) compared to fasting. Zaleplon systemic exposure (AUC) and elimination half-life were not significantly affected.

MANAGEMENT: Patients receiving zaleplon should be advised to avoid the consumption of alcohol. For faster sleep onset, zaleplon should not be administered with or immediately after a high-fat or heavy meal.

References

  1. (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories

Switch to consumer interaction data

Moderate

deferasirox food

Applies to: deferasirox

ADJUST DOSING INTERVAL: According to product labeling, the bioavailability of deferasirox was variably increased when taken with a meal.

MANAGEMENT: To ensure consistent plasma drug levels, deferasirox should be taken on an empty stomach 30 minutes before eating preferably at the same time everyday.

References

  1. (2005) "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.